Advances

In an analysis of the SUNBEAM and DAYBREAK studies, researchers aimed to compare the effects of ozanimod and intramuscular interferon on Symbol Digit Modalities Test scores among patients aged 18 to 55 years with relapsing multiple sclerosis.